Your browser doesn't support javascript.
loading
Comparison of acalabrutinib plus obinutuzumab, ibrutinib plus obinutuzumab and venetoclax plus obinutuzumab for untreated CLL: a network meta-analysis.
Sheng, Zhixin; Song, Shilei; Yu, Miao; Zhu, Hongguang; Gao, Anran; Gao, Weijie; Ran, Xuehong; Huo, Da.
Afiliación
  • Sheng Z; Department of Hematology, Weifang People's Hospital, Weifang, Shandong, China.
  • Song S; Department of Emergency Neurology, Weifang People's Hospital, Weifang, Shandong, China.
  • Yu M; Department of Stomatology, Weifang People's Hospital, Weifang, Shandong, China.
  • Zhu H; Department of Stomatology, Weifang People's Hospital, Weifang, Shandong, China.
  • Gao A; Weifang Medical University, Weifang People's Hospital, Weifang, Shandong, China.
  • Gao W; Weifang Medical University, Weifang People's Hospital, Weifang, Shandong, China.
  • Ran X; Department of Hematology, Weifang People's Hospital, Weifang, Shandong, China.
  • Huo D; Department of Oncology, Weifang People's Hospital, Weifang, Shandong, China.
Leuk Lymphoma ; 61(14): 3432-3439, 2020 12.
Article en En | MEDLINE | ID: mdl-32862749
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Tipo de estudio: Observational_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: China
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Tipo de estudio: Observational_studies / Risk_factors_studies / Systematic_reviews Límite: Humans Idioma: En Revista: Leuk Lymphoma Asunto de la revista: HEMATOLOGIA / NEOPLASIAS Año: 2020 Tipo del documento: Article País de afiliación: China